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Executive Summary 
The growing burden of disease faced by low-income countries due to the ever-present 
infectious diseases and the steadily growing prevalence of non-communicable diseases 
severely strains most public health services and causes enormous economic losses in 
addition to human suffering. This crisis has challenged non-healthcare sector players to 
become involved in order to stem the tide of losses. Particularly employers in the public and 
private sectors have been investing in the health and wellbeing of their employees as a way 
to dampen the productivity losses caused by this enormous burden of disease.  
Tools for enabling these non-healthcare specialists to make informed, evidence-based 
investment decisions to safeguard and improve the health and well-being of their human 
resources and further to support the business case for these investments have so far been 
lacking.  
The GIZ in Ghana commissioned this study to explore the profitability of existing employee 
wellbeing programmes in Ghana and to support the development of an economic model 
which translates the epidemiological profile of the employees into understandable measures 
of productivity losses and which enables cost-benefit analysis of interventions being 
considered to alleviate these losses.  
The model succeeded in quantifying and prioritizing the most important causes of 
productivity losses due to morbidity and mortality. The main findings indicate that top five 
account for well over half of the losses: 
  
Number Top five causes of 
productivity losses 
Percent 
% 
1 Malaria 24.99% 
2 Hypertension 12.42% 
3 HIV/AIDS 7.34% 
4 Skin diseases 5.87% 
5 Obesity 5.65% 
  
Total 56.27% 
Table 1: Top five causes of productivity losses, percentages of total. 
The remaining top causes of productivity losses individually account for less than 5% of the 
total, which indicates that investments in interventions to alleviate them will need also to be 
modest in order to achieve a net benefit. 
The research hypothesis of this study, that there is a positive net benefit to be realised 
by employers within a viable (business) time-frame from investing in needs-based, 
best practice health and wellbeing interventions for its employees, has been supported 
by the study results. These results indicate that, based on very conservative assumptions of 
productive work days lost, employers can recoup most or all of their annualized investment 
within each year, for many interventions.  
  
 
 ix 
Disease / Risk Factor Intervention Type 
Cost / Benefit 
Ratio Net Benefit [GHS] 
Malaria 
MAL-1 :  Insecticide-
treated bed nets (ITN) 0.8227 2'873.51 
 
MAL-3 :  Indoor residual 
spraying (IRS) 1.1140 -1'846.49 
 Both MAL-1 and MAL-3 1.3636 -8'367.44 
Non-acute diseases 
& risk factors 
Health risk assessment 
(in-house) 2.8585 -12'548.21 
 
Health risk assessment 
(go to doctor) 5.2579 -28'748.21 
Table 2: An example in summary form of the results of the CBA for suggested interventions.  
Moreover, the economic model developed permits employers to "test" any interventions 
targeting any of a wide range of priority causes of morbidity and mortality affecting its human 
resources. The testing allows great flexibility to change inputs for variations of interventions 
in order to calculate cost benefit ratios and the net benefit for each. 
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1 Introduction 
1.1 Statement of the problem 
The double burden of infectious and non-communicable diseases is a serious problem in 
Ghana, as it is throughout sub-Saharan Africa and elsewhere, and has adverse effects on 
both the population in terms of morbidity and mortality and the economy in terms of rising 
health care costs and losses of productivity2. 
Infectious diseases such as malaria and tuberculosis (TB) are major causes of morbidity and 
mortality in Ghana. Most recent data report 3.2 million annual cases of malaria3, with an 
estimated number of deaths of 23,500 annually4. The estimated prevalence rate of TB is 363 
cases per 100.000 population and the number of new cases per year 202/100’000 population 
in 20084. In 2007, the national prevalence of HIV in the adult population between 15 and 49 
years was 1.9%5, with an estimated number of HIV positive adults – with or without 
symptoms of AIDS - in Ghana of 260,0004.  
The morbidity and mortality from non-communicable diseases (NCD) such as cardiovascular 
disease and cancer, also places a huge burden on the country2. Cardiovascular disease and 
breast cancer (in woman between 15-59 years) are among the top ten contributors to 
mortality4, and their disease burden is expected to increase over the coming decades6. 
In line with these developments, risk factors associated with these non-communicable 
diseases are very prevalent in Ghana. For example, hypertension has been shown to have a 
prevalence of 27.4% (among urban civil servants)7 8 and obesity 14.1% (in an urban 
population)9. 
Infectious and non-communicable diseases are together a huge burden for the healthcare 
system, society and economy. Particularly the HIV-infected often suffer from stigma and 
discrimination at workplaces, and within their families and communities. Private households’ 
capacities to generate income are jeopardised, and their financial capital is being diverted to 
respond to diseases, especially as many households have no access to social protection.  
Infectious and non-communicable diseases also severely affect private companies, which 
lose huge numbers of their skilled workforce to diseases, leading to high employee costs and 
lower profit margins. In order to curtail the rising employee related costs, private companies 
are applying measures to improve the health situation and the productivity of their workforce, 
which can be assumed to translate into increased profits and ultimately an enhancement of 
the national economy.  
Broader but equally important factors related to the spread of infectious and non 
communicable diseases may be the lack of basic health and social protection, employees’ 
unawareness of measures to prevent diseases as well as lack of access to adequate 
diagnosis and treatment facilities. Although the Government of Ghana in 2005 introduced a 
National Health Insurance Scheme (NHIS) for all Ghanaians, approximately one third of the 
population remained unregistered by mid-201010. Education and sensitisation is needed for 
the NHIS to win the trust of most Ghanaians. Other social protection measures such as 
retirement packages, property, accident and life insurances are not very common. This calls 
for private measures complementing the initiatives taken by the government. 
In order to overcome these constraints which all negatively impact on the health and 
productivity of employees, private and public companies have begun to implement so-called 
“Employee Wellbeing Programmes” which in most cases evolved out of HIV workplace 
programmes (WPP). Such workplace programmes addressing a broader spectrum of 
preventive and treatment measures beyond HIV/AIDS are already being implemented in the 
Ghana Community Network Services Limited (GCNet)11 together with the Revenue Agencies 
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(RA) and for Aqua Vitens Rand Limited (AVRL) with the Ghana Water Company Limited 
(GWCL). 
A further EWP has been implemented from mid-2010 among GIZ Ghana national staff 
members working at the GIZ Ghana HQ and for the many programmes being supported by 
GIZ in Ghana.   
1.2 Purpose of study 
The aim of the GIZ-supported project Implementation of sustainable and comprehensive 
Employee Wellbeing Programme is: Employees of GCNet, the GRA, the GWCL and the 
AVRL, their core families as well as members of their immediate communities have an 
improved access to health, social protection and financial counselling services as well as to 
education, prevention, treatment and care facilities that are related to infectious and non-
communicable diseases.  
The general objective of the health-economic analysis (cost-benefit analysis: CBA) 
was to compare costs and monetary benefits of offering different preventive and treatment 
packages within the Employee Wellbeing Programme from the perspective of the 
employer. The aim was to assess the economic value of these workplace health promotion 
programmes from the employers’ perspective. To this aim, a model has been developed that 
can be used by the companies (that generally bear most of the costs, direct and indirect, of 
workers’ illness) to evaluate the economic benefit of adopting such a programme. The results 
of the CBA and appropriate sensitivity analyses should provide insight into whether such a 
programme is worthwhile for the employer and how net benefits (or costs) vary according to 
a change of assumptions (e.g. with regard to the epidemiological situation), a change of the 
constituent parts of the package (or screening intervals) or a change of the target population 
(employees, their family members, and members of their immediate community). 
1.3 Significance of the study 
There is very little evidence, if any, of the net benefit to the employer of investments in 
employee health and wellbeing programmes in Ghana, specifically, and in Africa, in general. 
This study contributes to the meagre evidence12 on the cost-effectiveness of employer 
investments in employee health and wellbeing interventions in the context of Ghana, sub-
Saharan Africa, and low-to-middle income countries, while acknowledging the substantial 
methodological challenges involved.  
The study also aimed to produce a user-friendly tool to aid employers in making the business 
case for investments in employee health and wellbeing. There is very little evidence of the 
use of needs-based models, based on the epidemiological profile of the worker population, to 
inform employer decision making for investments in employee wellbeing programmes. This 
study aimed to provide a tool which enables employers to estimate the financial burden of 
any particular illness or condition which may be expected to affect the employees' 
productivity and to help prioritise investments in interventions to address the most 
"expensive" illnesses (from an employer perspective) affecting the employee population. 
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2 Background 
An Employee Wellbeing Programme (EWP) has been initiated in mid-2009 and implemented 
at GCNet and the Ghana Revenue Agencies (GRA), which are partial owners of GCNet. The 
EWP serves as an expansion to the recently ended HIV & TB Workplace project (WPP 2006-
2009) for the GRA. The WPP was a Public-Private-Partnership (PPP) project with GCNet 
being the private donor. The employees of GCNet have been included in the EWP because 
of the highly successful WPP. The EWP aims at reaching out to approximately 38,000 
persons, comprising: 
- Employees of GCNet with staff strength of 80 and their core families (partner and 
maximum six children) of approximately 280. 
- Employees of the Ghana Revenue Agencies comprising of the Customs Excise and 
Preventive Services (CEPS), Internal Revenue Service (IRS) and Value Added Tax 
Service (VATS) in the ten regions of Ghana with a staff strength of 7,700 and their core 
families of approximately 15,000. 
- Members of the employees’ immediate communities (approximately 15,000) comprising 
of at least 60% women. 
Building on the experience made in other projects where Employee Wellbeing Programmes 
have been built around existing HIV workplace programmes, this PPP first focuses on the 
facilitation of access to prevention, testing and treatment facilities for HIV/AIDS and other 
infectious and non-communicable diseases. The immediate communities are involved in this 
first component. Gradually this component will be complemented by the facilitation of access 
to social protection and financial counselling for the employees and their families, which is 
innovative in so far as these components will create a more comprehensive understanding of 
health protection among the partners than has so far been done in more “classic” workplace 
programmes.  
A second Employee Wellbeing Programme (EWP) has been initiated and implemented at the 
state-owned Ghanaian water agency GWCL which was restructured with the assistance of 
the World Bank in 2006. A tendering competition for the production and dispersion of drinking 
water in Ghana was won by AVRL, a joint venture owned by “Vitens BV”, a Dutch publicly-
owned utility company which holds 51% of AVRL´s shares and “Rand Water”, a South 
African utility company with a 49% shareholding. AVRL therein assumes the responsibility of 
the water operator, while GWCL is the owner of all relevant assets with responsibility for 
investments. AVRL has grown to nearly 3,000 employees in 2011, among which 2,900 are 
Ghanaian. GWCL has 80 employees.  
Using the same approach as for the GCNet and GRA EWP (expansion of the previously 
successful HIV & TB workplace programme, WPP where AVRL is the private donor and with 
the support of GIZ), AVRL and GWCL implemented in mid-2009 an Employment Wellbeing 
Programme reaching out to approximately 39,000 people, comprising of employees of AVRL 
and GWCL with staff strength of approximately 3,000 and their core families of approximately 
9,000 and members of the employees´ immediate communities (approximately 27,000) 
A further EWP has been implemented from mid-2010 among GIZ Ghana national staff 
members working at the GIZ Ghana HQ or for one of the many programmes being supported 
by GIZ in Ghana.  
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2.1 Results of literature review  
2.1.1 Procedure description 
A literature review was conducted to find relevant articles and other publications relating to 
employee wellbeing programmes from the online databases of PubMed(NLM), 
OvidSP(Medline), GBV, LISTA at EBSCO, Library of Congress, U Basel Bern, NEBIS and 
Web of Science(TS) using the EndNote X4© software and with the assistance of the Head 
Librarian at the Swiss TPH. The key search words included (among others) occupational 
health, employee health, workplace health, cost effectiveness, meta-studies, Ghana, Africa, 
international. 472 references from the period of 1984 to 2010 could be identified, which have 
been scanned on the basis of title and abstract to extract the most relevant studies for this 
economic modelling study. The 300 search results from the period 2000 to 2010 were given 
particular attention.   
2.1.2 Little evidence from Africa 
The search produced a wealth of studies reaching back into the 1970s in the USA, but very 
few studies from Africa. Zungu et al (2007) conducted an international review of 45 "high-
quality" studies of workplace health promotion (WHP) programmes of which 41 were from 
USA, Europe and Australia. Interestingly one conclusion of this study was that most of these 
programmes tend to reach healthy workers in the best companies and the authors suggest 
that WHP will increase the inequality of health in the world.12  
2.1.3 Workplace health promotion programmes are cost-effective 
The reviewed literature suggests that there is sufficient evidence to conclude that well-
designed workplace health promotion programmes are generally effective and cost-effective. 
Pelletier (2009) has systematically reviewed studies of workplace health programmes in the 
USA which have been published in peer-reviewed journals and his seventh up-date adds 16 
new studies from 2004 - 200813. He concludes that the vast majority of the 153 studies 
reviewed indicate positive clinical and cost outcomes.  
2.1.4 Methodology vs. pragmatism 
There is a very clear trade-off in studies of workplace health programmes between satisfying 
the needs of employers in making evidence-based investments in employee health and the 
expense and constraints of conducting rigorous research. Pelletier notes a trend away from 
true experimental designs and towards companies conducting focussed or non-experimental 
demonstration disease management programmes on areas that are of specific importance to 
the employer. He suggests that these innovative studies can be the precursors of more 
rigorous research. Pelletier also quoted a report of the WHO European Working Group on 
Health Promotion Evaluation, WHO 1998 which noted that "the use of randomized control 
trials to evaluate health promotion initiatives is, in most cases, inappropriate, misleading and 
unnecessarily expensive." 13  
2.1.5 Measures of productivity losses 
Baiker et al (2010) conducted a systematic review of peer-reviewed studies in the USA which 
satisfied criteria of having a well-defined intervention and well-defined treatment and 
comparison groups, even if these were not strictly randomly assigned. Their sample of 32 
studies looked at either reduction in health care costs of employees or absent days or 
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both. All but one study showed a positive return on investment in terms of reductions in 
health care costs, absent days or both. 14 
There is much discussion about how to measure and cost the employee health-related 
"problem" and the benefits and the value of these benefits to the employer of interventions 
intended to address that problem. Most studies have limited these measures to those factors 
which are relatively easily measured, such as health care costs and sick days.  
2.1.6 Presenteesim: base of the iceberg? 
Another element of productivity losses, namely presenteeism has become more and more 
interesting to employers for the reason (among others) that absenteeism tends to disappear 
when there is general economic pressure. Employees tend not to risk taking sick days, which 
may be used as a criterion for deciding which employees are the least productive and should 
be laid off first.15 Presenteeism has been defined in many ways, but Chapman (2005) 
suggested the following practical definition: "The measurable extent to which health 
symptoms, conditions and diseases adversely affect the work productivity of individuals who 
choose to remain at work."16  
Estimates from numerous studies indicate that presenteeism may account for an additional 
loss of productivity ranging from 25% -750% of the time lost due to sick days.17 18  
2.1.7 Best-practice elements of workplace health promotion programmes: 
The debate is recently focussing around which interventions and packages of interventions 
should be provided. There are several published articles which describe the elements 
common to successful workplace health promotion programmes. Goetzel and Pronk (2010)19 
summarised from a series of benchmarking and best-practice studies the following promising 
features of such programmes as 1) organizational commitment; 2) incentives for employees 
to participate; 3) effective screening and triage; 4) state of the art theory- and evidence-
based interventions; 5) effective implementation; and 6) ongoing programme evaluation. 
They added that O'Donnell et al (1997) considered executive management support, 
employee input when developing goals and objectives, and a wide variety of programme 
offerings contributed to programme success.20  
An additional aspect of this debate is a clear shift from workplace programmes focussing on 
providing treatment of specific diseases or conditions towards addressing the reduction of 
risk factors in more preventive approaches to employee health and well-being. Goetzel et al 
(2009) shows that "research with employers has documented the relationship between health 
risk status and important work-related cost and productivity outcomes and this research 
suggests that risk reduction among workers may be a practical way to improve these 
outcomes."21 This brings the field of workplace health promotion programmes more in line 
with the global debate on health and well-being.  
2.1.8 Epidemiological profile for Ghana 
A second search was conducted to collect data for the epidemiological profile for Ghana. 
The resources of the WHO, the Global Burden of Disease reports, the Ghana Health 
Service22, the Ghanaian National Health Insurance Scheme and some disease-specific 
studies for Ghana were tapped in order, as far as possible, to establish an age-sex 
disaggregated profile outlining the top causes of mortality and morbidity for formally 
employed, urban employees in Ghana which best match the target employee populations of 
the WPP/EWP. Data in consideration of key risk factors has also been gleaned from these 
sources. The available data were in many cases lacking for this specific population and it 
was necessary to make assumptions and triangulate the data from several sources to 
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achieve a reasonable estimation of the burden of disease expected for this population of 
employees.  
The resources available online from WHO-Choice23 provide(d) key information regarding 
best-practice cost-effective interventions, both preventive and curative for the most relevant 
diseases and conditions for the study population.  
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3 Methodology 
3.1 Purpose of research and research hypotheses 
The general objective of this economic analysis (cost-benefit analysis: CBA) is to compare 
costs and monetary benefits of offering different preventive and treatment packages within 
the Employee Wellbeing Programme from the perspective of the employer. To this aim, a 
framework has been developed that can be used by the companies (that generally bear most 
of the costs, direct and indirect, of workers’ illness) to estimate the cost to the employer 
arising from the major illnesses and conditions affecting the employees and to estimate the 
potential benefits of investing in interventions to address these conditions and illnesses as 
elements of an employee wellbeing programme. The results of applying the economic model 
and sensitivity analysis should provide insight into whether such investments in EWP 
elements are worthwhile for the employer and how net benefits (or costs) may vary according 
to a change of assumptions (e.g. with regard to the epidemiological situation), a change of 
the constituent parts of the package (or screening intervals) or a change of the target 
population (employees, their family members, and members of their immediate community). 
 
Research Hypothesis:  
There is a positive net benefit to be realised by employers within a viable (business) time-
frame from investing in best practice health and wellbeing interventions for its employees.  
3.2 Population  
The target population for this study consists of the employees of the agencies and 
companies described more fully in preceding chapters of this report. The epidemiological 
profile for this population has been estimated by adjusting appropriately the national 
epidemiological profile for the entire Ghanaian population. Such factors have been taken into 
account as: 1) the mostly urban setting of the employees, 2) the employees are formally 
employed, 3) the nature of their work is mostly white-collar, office-based with some 
exceptions, such as the many officers of the Customs Excise and Preventive Services 
working at the mostly rural outposts at the national borders and the employees of the AVRL 
who are responsible for service and maintenance work of the (urban) water supply system. 
As this study is based partly on historical data for the entire workforce and forecasts the 
costs of health problems and the benefits and costs of the interventions in employee health 
and wellbeing based on an economic model, there is no sampling and also there are no 
control groups. It is a recommended further step to conduct a longer-term prospective study 
to establish the accuracy of the forecasts from the model and also to establish the actual 
costs and achieved benefits from the interventions undertaken.  
This study has also excluded the family and community members of the employees targeted 
by the WPP/EWP as most interventions of these programmes focussed on the employees 
themselves, with the exception of awareness-building actions which also targeted the 
families and members of the wider community. 
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3.3 Instrumentation (include copy in appendix) 
3.3.1 Description of Model (Excel tool) 
The Excel tool implements the model algorithms used to calculated costs due to absence 
days and presenteeism based on the specific epidemiological profile and data related to 
disease treatment. It allows the user to specify a set of input parameters such as data related 
to employees, disease-specific scaling factors and global settings.  
It consists of several work sheets which are grouped into various categories related to user 
input, the display of model predictions, and tables of baseline data. 
For more details and a user guide to the Excel tool please see Appendix 7.2 
3.3.2 Model equations 
For a description of the model equations and algorithms use please refer to Appendix 7.1 
3.3.3 Survey tools and data collection from study target employers  
As part of our mandate to develop a modelling tool to enable employers to calculate the cost 
of individual sources of productivity losses, it was necessary to concentrate on data which 
would be readily available to the employer, without needing to engage in a time-consuming, 
potentially expensive search for model input requirements. 
This was the focus of data collection efforts from the target population employers based 
mostly in Accra with the intent of collecting the following historical data:  
1 Annual staff strength, number of staff members each year disaggregated by sex 
2 Annual total in new Ghana Cedis (GHS) for staff medical expenses 
3 Annual number of medical claims for reimbursement made 
4 Annual total in GHS of salaries expense 
5 Annual total number of sick leave days disaggregated by sex 
6 Annual number of staff turnovers due to illness, disability or death disaggregated by sex 
7 Annual number of compassionate leave days 
Table 3: Historical data requested from study target employers. 
The survey tools prepared for this study and which were sent in advance of the data 
collection mission by the Principal Investigator (PI) were designed to collect these data from 
the employers of the EWPs from their human resources (employee) and financial records for 
as many years back as possible. The Excel-based survey tools were introduced to the 
employers by GIZ ReCHT officers responsible for the two EWPs included in the study. The 
employers responded through these officers that the tools were too detailed and not easily 
understood. They suggested a simplified version which was then agreed to be used.  
The lead time of approximately three weeks before the mission of the PI sensitized the 
employers and the GIZ officers as to the extent of the information required for the study.  
It was beneficial during the PI mission to Accra to engage the GIZ officers and the employer 
representatives in clarifying discussions of which information was needed and which 
information was possible to collect. For the GRA/GC-Net EWP, the PI was able to meet with 
each of the employers and the GIZ officer responsible at least once to clarify and agree on 
the information requirements and availability. For the GWCL/AVRL EWP, it was possible to 
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arrange a preliminary meeting with the GIZ officer and the employer representatives of the 
AVRL to clarify the data needs and availability also with regard to the GWCL.  
During these meetings, two goals were being pursued:  
 
1. collecting historical data which would facilitate an assessment of the costs and 
benefits of the previous HIV/AIDS WPP and the current EWP including the data 
mentioned above as well as the following:  
Table 4: Programmatic data requested from study target employers, GIZ ReCHT EWP. 
and  
2. collecting data and information which could be used to compare with the model 
estimates and help to refine these estimates. 
Many discussions were held with employers and GIZ-ReCHT officers to explain the study 
procedures and goals and to understand more of the local conditions and qualitative 
elements of these WPP and EWP. These discussions were very fruitful for the PI in order to 
inform the model parameters and the need to base it on very minimal data inputs which 
would be reasonably easy to obtain and also to understand by the employers who are 
subsequently to use the model for needs-based decision-making in investing in appropriate 
interventions.   
The data collection exercise began before the mission, but most data was collected 
subsequently over the many weeks following the mission. The PI engaged in an intense 
exchange with the employers through the GIZ officers to remind of requested information, to 
verify, correct, and complete data. After many weeks, it became apparent that some 
employers were not able to release any information required, notably the GWCL and the 
AVRL, and the GRA employers were forthcoming with much of the requested data, but in a 
piecemeal, incomplete way. 
At the time of writing this study report, the data available was mostly insufficient to pursue the 
first goal (a historical CBA of the WPP and EWP), and only one data set, notably that of the 
VAT of the GRA, was complete enough to enable a useful comparison with the model 
estimates based on the same employee population inputs. 
Please refer to table 13 in Appendix 7.3 for a summary table of data sets received. 
 
3.4 Procedure 
3.4.1 Step one: Establishing the employee epidemiological profile 
 
 GIZ ReCHT EWP information   
8 Monitoring & Evaluation reports 14 
EWP programme  financial reports for 
programme expenses 
9 Semi- and Annual reports 15 WPP dedicated staff costs 
10 KAP GTZ study report 16 EWP dedicated staff costs 
11 Baseline study 2008 17 Organisation charts current 
12 HIV/TB study 2008 18 Organisation charts previous 
13 
WPP programme financial reports for 
programme expenses 
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Morbidity and mortality 
 The first step in this study was to determine the most important contributors to morbidity and 
mortality from the national health statistics available from the WHO, the Global Burden of 
Disease Programme and from the Ghana Health Services as far as available disaggregated 
by sex and age groups. This allowed finding the relevant incidence, prevalence and mortality 
rates which most closely match the target populations of the study, namely the beneficiaries 
of the WPP/EWP. Some of the data available from the WHO Global Burden of Disease 
reports were segregated sufficiently to extract the needed information for urban, adult 
populations by sex. Some of the data was not sufficiently segregated and needed to be 
calculated as far as possible from secondary reports from the GHS and from the NHIS 
operations manual from 200824, which provided additional detail from which it was possible to 
approximate the relative incidence of the major causes of mortality and morbidity.  
These data were further disaggregated through calculations into approximate proportions of 
outpatient and inpatient incidence based on the data available in the NHIS operations 
manual mentioned above which provided outpatient incidence and also numbers of 
admissions for each disease listed. 
It was possible to establish a relative ranking of the major causes of morbidity and mortality 
for an urban population, disaggregated by sex and also to approximate the relative 
proportion of inpatient and outpatient incidence for these same diseases.  
Some of the classifications of diseases provided in GHS reports did not follow the standard 
classifications used by WHO and these needed to be re-allocated to the relevant WHO 
disease classifications in order to establish a final definitive list ranking the most relevant 
causes of morbidity and mortality for the Ghanaian urban adult population segregated by 
sex. The purpose here was not to significantly estimate the incidence of each particular 
disease in the urban adult population but to establish a list of the most influential causes of 
morbidity and mortality and to establish their relative importance in comparison to each other.  
 
Risk Factors 
The burden of disease statistics found for Ghana also reported the prevalence of several 
important risk factors, also disaggregated sufficiently to get an impression of the relative 
importance of these for an urban, adult population by sex. Some recent studies also 
focussed on a very comparable population of civil servants in Accra for hypertension and 
obesity. These are particularly interesting in relation to the discussion of the shift towards 
reducing these health risks as a more cost-effective way to improve the productivity of the 
employees as compared to interventions of a curative nature. 21 
The study from Goetzel et al 2009 estimated the presenteesim effects for various risk factors 
for a large population of Novartis employees in the USA, which showed the relative effect on 
worker productivity due to the presence of risk factors. These estimates were used in 
combination with the Ghana prevalence rates of health risk factors mentioned above to 
estimate productivity losses due to presenteeism among the employee populations in this 
study.   
 
Mental illness? 
There was a dearth of relevant statistics concerning mental health causes of morbidity and 
mortality in Ghana, which can be suggested to grossly underestimate their influence on the 
productivity of the target population, but were excluded from the model due to lack of 
verifiable relative prominence compared to somatic causes of morbidity and mortality.   
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3.4.2 Step two: estimate the average length of an episode of each illness 
This step is key to this economic analysis in order to convert the burden of diseases 
established in step one from measures of morbidity and mortality into measures of work days 
lost per episode of each disease or condition.  
 
YLD route 
This was first attempted using the standard calculations published by Murray and Lopez 
(1996)25 for determining, for each disease and WHO region, the YLDs (= Years Lived with 
Disability) comprising of the average intensity of an episode of disease (disability weight) 
multiplied by the average length of the disability measured in time. The average durations of 
an episode of illness were obtainable only for three diseases, namely malaria, upper 
respiratory tract infections and diarrhoeal diseases and these have been used in the 
economic model as an optional proxy indicator for estimating the average number of work 
days lost due to sickness (absenteeism and presenteeism) for a case of each of these 
illnesses.  
For the other diseases and conditions, the available data was not available to use directly, as 
for the three mentioned above.  Nor was it possible to calculate it using the standard formula, 
though the use of the DISMOD II software which has been developed for the Global Burden 
of Disease studies was recommended for this purpose. The lack of corresponding WHO 
Global Burden of Disease incidence rates needed to complete the calculations disease by 
disease frustrated the use of this seemingly promising tool to estimate the average durations 
of an episode of illness. 
 
"Average length of stay in hospital" route 
It was necessary to seek another solution, which we based on the Ghanaian National Health 
Insurance Scheme Tariff and Benefits Package Operation Manual 2008. This provided in its 
Annex B a list of the causes of hospital admissions with an average length of stay. The 
average durations of an outpatient episode of illness were assumed to be the same as the 
average length of stay in hospital for an in-patient case. These estimates are adjustable 
through a scaling factor to calculate the average number of sick days per outpatient case for 
the employees. 
Annex B
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Stay in Hospital - Top Twenty Causes of Morbidity                         
 
        
Disease 
Average length of 
stay in hospital 
[days] Comments Reference 
Malaria 3.2   A 
Infection upper respiratory 
tract 3.6   A 
Diarrhoeal diseases 3.4 Based on data for 'gastroenteritis' A 
Skin diseases 8.3   A 
Hypertension 4.3   A 
Home/occupational 
injuries 6.2   A 
Acute eye infections 7.1   A 
Pregnancy and related 
complications 3.8   A 
Rheumatic and joint 
diseases n.a. No data available A 
Anaemia 4   A 
Intestinal worms 4.7 
Based on data for 'other disease 
digestive tract' A 
Gynaecological conditions 3.8 
Based on data for 'complicated 
pregnancy' A 
Malaria in pregnancy 3.8 
Based on data for 'complicated 
pregnancy' A 
Pneumonia 4.6   A 
Acute ear infection 4.2   A 
Typhoid fever 6.7   A 
Road traffic injuries 4.6   A 
Other oral conditions 3.1   A 
Dental caries n.a. No data available A 
Diabetes Mellitus 8.1   A 
Table 5: Stay in Hospital - Top Twenty Causes of Morbidity. 
 
Outpatient or inpatient? 
A further refinement in determining more accurately the lost productivity was possible based 
on the same NHIS operations manual which helped to establish the proportion of cases of 
each illness which were serious enough to require admitting the patient to a hospital (relative 
to outpatient cases listed in its Annex A). 
 
Annex A
 
3.4.3 Step three: Estimate the burden of disease in terms of number and cost 
of work days lost for the target employee populations 
 
Productivity losses measured in work days 
 There are five variables which combine to estimate the loss of productive days for each 
illness:  
1. the outpatient average length of illness episode;  
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2. the work days lost due to presenteeism as an additional proportion of these sick days;  
3. the lost productive days (presenteeism) due to the prevalence of health risk factors; 
4. the additional days lost for those cases which would be admitted to hospital; and 
lastly 
5. the very great loss of days caused for the very few expected cases of death of the 
employee. The estimated days lost in this case are based conservatively on the death 
benefits of salary for six months26.  
 
Treatment costs are history?  
The estimation of the cost of treatment of these illnesses and conditions has recently 
become irrelevant, due to the obligation of all employees in the target populations to register 
with the NHIS and seek health care from the GHS. These services27 are provided free of out-
of-pocket fees in lieu of the monthly premium of 2.5% of the employees' salaries being 
deducted for the NHIS. Thus, the actual treatment costs which the employers were covering 
for services offered by NHIS as expenses up to and including 2010, have in 2011 become 
negligible.  
There were also considerations of the employers providing a top-up insurance package for 
its employees to cover those items not covered by the NHIS or to be able to obtain the 
covered services from non-GHS sources in the private health care sector. These costs are 
also assumed to be fixed costs to the employer which are independent of and do not change 
according to the health care services the employees actually use. There may still be a very 
few cases in which the employers may be required to cover very high costs for treatment 
procedures not covered or fully covered by the insurance schemes provided, such as for 
planned heart surgery, etc. These have been assumed to be exceptional cases and have not 
been explicitly considered in this model. 
 
Input employee numbers 
The employer may enter the employee numbers by sex into the model, which then estimates 
the number of work days to be lost for the expected number of cases per disease and 
condition. These estimates will be shown for sick days (absenteeism due to sickness: 
outpatient and inpatient), death benefit days and also for those due to presenteeism as an 
additional proportion of the sick days, and presenteeism due to the presence of risk factors. 
Finally, the model shows a total number of productive days lost per disease or condition and 
calculates of the total number of productive days lost for the employee population.  
These estimates made by the model in the base case have been calibrated and verified 
through triangulation against the historical data collected from the employers on sickness 
days (not available disaggregated by disease). Unfortunately, the quantity and also the 
quality of these data were less than optimal and can only give a very rough estimate of the 
historical annual total sick days. The only data set which was complete for this purpose were 
those of the VAT section of GRA, for the four years from 2007 - 2010, for an employee 
population of just over 1000.  
 
Costing a day lost 
Having, up to this point in the model, established a forecast of the number of days of lost 
productivity attributable to each disease and condition annually for the target population of 
employees, it is then possible to multiply this by a value of a work day based on a function of 
the total annual salary expense divided by the total number of employees to get an average 
annual salary per employee. This annual average salary is then divided by the number of 
working days available each year after deducting public holidays and annual leave. This 
figure has been estimated as a base figure of 217 days annually, but may be changed in the 
inputs to reflect the particular regulations of the employer using the model. Indeed, it is 
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possible for the model to be used for any sub-population of employees, whose real salary 
costs are known to obtain a more accurate estimate of the cost of the work days lost. 
For alternative methods, please refer to Section 3.9 below. 
 
Ranking the losses 
The model calculates the annual "cost" of each illness and condition as a function of lost 
productive days and the average salary cost per work day. Based on this calculation, the 
model then provides a list ranking the diseases and conditions in terms of expected losses of 
productivity based on the salary cost of the expected days lost, firstly for each element: 
outpatient sick-days, inpatient sick-days, death benefits, presenteeism as an additional 
proportion of outpatient sick days and presenteesim based on the presence of risk factors 
and then finally as a total of all of these. This information already provides the employer with 
a very useful estimation of the most expensive sources of lost productivity relative to each 
other and of the potential cost savings to be gained by addressing investments according to 
these specific sources.  
3.4.4 Step four: categorize and provide examples of best practice 
interventions for each major cause of "business" losses 
The prioritized list of diseases, conditions and risk factors established in the previous steps of 
the model are then categorized according to the following logic. In analysing the list, it 
became evident that there were some limitations affecting the choice of interventions which 
an employer could undertake. With reference to the caveat concerning treatment costs 
outlined in step three above, it was possible to sort the list into three categories:  
1. Malaria which has been estimated to account for about a quarter of the productivity 
losses.  
2. Non-acute diseases, conditions and risk factors which are seen to account for 
about half of the productivity losses.  
3. Acute diseases and conditions which have been suggested by the model to explain 
the remaining productivity losses.  
 
Category 1 - Malaria 
For malaria there are preventive interventions available which an employer may undertake 
as elements of an employee well-being programme. Based on WHO-CHOICE23 information 
and other sources28 29 30 a limited set of cost-effective best-practice preventive interventions 
for malaria has been included in the model as potential elements of an employee wellbeing 
package. These are listed along with their expected effectiveness in preventing incidence 
and mortality.  
These interventions become even more attractive due to the possibility to externalize all or 
most of the costs which may be covered by global malaria initiatives. In this case, the inputs 
for the annualized cost per employee covered may be adjusted downward, resulting in 
correspondingly higher net benefits. 
 
Category 2 - Non-acute diseases, conditions and risk factors 
For this category, it is clear from the literature that it is in the interest and ability of the 
employer to offer any number of preventive interventions20 in order to reduce the health risks 
which would lead to serious burden of disease for the employees if left unattended and to 
encourage diagnosis and treatment where needed.  
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The literature suggests that one of the first and necessary (but not sufficient) steps in any 
EWP is a health risk assessment19. It is therefore suggested here that this be promoted by 
the employer, in order, at least to encourage each employee to obtain regular health check-
ups. This should result in reductions in the burden of disease of the employees by placing 
the employees into a doctor-patient relationship where all of the conditions may be 
diagnosed and treated. In this case, the effects are difficult to estimate even through actual 
observation, due to the variety of diseases and risks which may be affected and also due to 
the varying time-frames in which an effect may be observable. 
It can be argued that treatment interventions should normally be considered within the 
framework of a doctor-patient relationship and not an employer-employee relationship. The 
threat of stigma faced at the workplace for people living with HIV, for example, illustrates the 
need for a confidential doctor-patient framework. That said, employer efforts to reduce 
discrimination at the workplace and in the communities could be considered here as an 
intervention in the model.     
Many preventive interventions may be appropriate within the employer-employee 
framework. Preventive interventions such as Information, Education and Communication 
(IEC) and awareness-building actions for health or diseases, as well as promoting behaviour 
change, e.g. promoting healthy diet, exercise, stress management, smoking cessation, have 
not been explicitly included as examples in the model, as these are quite variable according 
to the context, type and scope and their effectiveness is often very difficult to estimate. For 
many preventive measures, the effects only become observable after several years of 
sustained implementation of an intervention. 
 
Category 3 - Acute diseases and conditions 
For these diseases and conditions, it is assumed that the employer can do little to influence 
prevention and treatment, aside from some occupational health interventions to prevent 
accidents at the workplace, for example. However, due to the acute nature of these 
conditions, it is further assumed that the employees will seek appropriate care as needed. 
Their cost-free access to GHS facilities for diagnosis and treatment due to obligatory 
enrolment in the NHIS supports this healthcare-seeking behaviour. The coverage by NHIF of 
most treatment costs relieves the employer of any significant role to play here. Therefore, 
there are no suggested interventions for possible inclusion in an EWP. 
The model allows for user inputs of any preventive or curative interventions, both for 
individual conditions and risks for all three categories and also for the entire category 
two.  
3.4.5 Step five: estimate the investment cost and the expected benefit for 
each intervention 
For all interventions, the model allows the following inputs:  
1. intervention name and description; 
2. percentage of coverage of an intervention in terms of the number of employees to be 
targeted for the intervention; 
3. intervention duration in years and annualized cost per year per employee; 
4. effectiveness of the intervention in terms of annual percentage of cases and deaths 
prevented. These estimations may require a survey of the literature or consultation 
with a public health expert. 
Based on these inputs, the model calculates the reduction in the burden of disease in terms 
of the value of saved work days, considering outpatient, inpatient and fatal cases prevented. 
The model then calculates a cost/benefit ratio as well as the net benefit: benefit less 
investment cost. These inform the employer of the relative effect of an intervention 
comparable to the others in the model and indeed to any other intervention where the CBR 
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has been calculated. All the interventions chosen or added to the model will be included in a 
summary table for ease of comparison.  
3.4.6 Step six: communicate results, with recommendations to GIZ and 
employers, disseminate model to employers 
3.5 Time frame 
This study is based on an economic model and the time frame is assumed to be one year, 
but the model can be adapted to several months and years, according to the availability of 
data and need. The changing of the scaling factors for the epidemiological profile and the 
annual salary and work days can be used to adjust the model for different time frames. The 
inputs for interventions can also be adjusted accordingly. For the annualized cost and effect 
inputs for interventions it is implicitly assumed that future years will be discounted 
appropriately.  
It is recommended to compliment this CBA study with a prospective study of at least one 
year duration (a multi-year study would be even more informative) which would enable a 
comparison of the model results against actual results in the contexts of the EWP target 
agencies and which would bring insights as to the robustness of the model and inform 
refinements, as well as provide evidence based on a more rigid research methodology. This 
would permit comparison of results in a wider context.  
3.6 Analysis  
Analysis has been conducted in two main areas: 1) the historical data collected from the 
employers and GIZ for the period covering the implementation of the WPP and the EWP and 
2) the model estimates compared to historical data.  
In the first area, the analysis was limited to plotting proxy indicators of productivity losses, 
namely annual statistics including absent days due to sickness, number and value of medical 
claims made, the number of employee turnovers due to sickness, disability and death against 
the investments made in the WPP and EWP to see if there were any visible indications of a 
possible association between the investments and an expected reduction in the productivity 
indicators.  
Given the methodological impossibility to draw any significant conclusions, these 
graphs should be viewed with greatest caution. In order to establish any cause and effect 
conclusions from investments made in EWPs, it would have been necessary to establish a 
clear baseline before any interventions in order to facilitate a before and after "treatment" 
study. In such a setting, with reliance on so many sources of potentially sensitive data, and 
with so many steps needed to collect and collate the data from each employer, it would be 
very difficult to control for the many sources of bias and confounding which could arise. The 
use of a random controlled trial would be the best option for preventing and controlling for 
bias, but as mentioned above, would require a inappropriately large investment, particularly 
in such a methodologically challenging "field" setting.    
As well, the intervention of the EWPs can be compared to moving targets, having evolved 
over the years from HIV/AIDS programmes to more comprehensive EWPs. Any effects which 
may seem plausible would be very difficult to accord to any particular elements of these 
programmes, or indeed at all to any programme as a whole.  For example, a reduction in 
medical claims made could be due to the increasing enrolment of employees in the NHIS, or 
to the EWP or both.   
The incompleteness and relatively poor quality of most of the historical data makes the 
analysis even more questionable. For example, the financial contributions made by the GIZ, 
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and the programme target employers were made on programme level and the productivity 
loss indicators were collected from each of the GRA components (VAT, RAGB, CEPS, IRS). 
These statistics were not complete across all components for any single indicator and thus 
could not be plotted against the programme investments in total. 
In the second area, that of the model, the analysis opportunities have been built in to the 
model in the form of scaling factors and user inputs which permit every user to adjust the 
model to reflect user-specific conditions. The default values of the scaling factors concerning 
the incidence of disease and prevalence of risk factors have been left to reflect published 
Ghana national health statistics, which have as far as possible been found for urban, adult 
populations disaggregated by sex.  
 
Calibration of the model 
The scaling factors for calculating the number of sick days due to outpatient morbidity have 
been set to 110% of the inpatient average duration of stay in hospital for each disease, as 
provided by the NHIS manual24 referred to previously. This value was established based on a 
comparison with the only complete data set available, that of the VAT employee population 
of just over 1000 which provided data sets for the years 2007-2010. The model was 
calibrated in accordance with the average of these four data sets so that the total sick days 
and death benefit days corresponded to the average of the historical data sets.  
The estimation of productive days lost (presenteeism) is based directly on a scaling factor as 
an additional proportion of the already established sick days calculated. This has been 
conservatively set as a default value of 25%. The scaling factor for estimating lost productive 
days due to the presence of health risks has been left at 1.0 (100%) to reflect the values 
suggested by Goetzel et al 200921 in their large scale study of Novartis employees in the 
USA. These scaling factors may be adjusted by the user to reflect local contexts.  
The cost calculation of the burden of disease estimate made by the model is based simply on 
the average gross salary cost of a work day. This value may be changed by the user by 
changing the inputs of employee numbers, total annual salary, works days per year, and the 
death benefit ratio. The lost work days are then multiplied by the average cost of a work day 
to estimate the cost of lost productive days. These costs have been left intuitively simple for 
easy use and adjustment by the user. 
The cost benefit analysis has been integrated into the model on the interventions, costs and 
benefits sheet, in which selected interventions have been provided with default estimates of 
cost, effect and benefit in GHS to then be able to calculate cost benefit ratios and makes 
calculations of net benefit. The user may adjust all of the elements on this sheet to reflect the 
local context or to perform "what if?" calculations. 
3.7 Validity and reliability 
The model-forecasted burden of disease for an employer has been partly validated in 
comparison to historical data collected from the target employers of the GIZ supported 
WPP/EWPs. The historical data includes data for actual sick days, as recorded for the 
employee population. The completion of more of the requested historical data sets would 
permit further validation and calibration of the model concerning the estimate of sick days 
and death benefit days. As more data sets become available, the possibility to check the 
reliability of the model estimate increases.  
The estimates of lost productivity due to presenteeism, both as a proportion of sick days, and 
as a reflection of the presence of health risks can only be confirmed through a prospective 
study in which employees are requested to complete a presenteeism survey as had been 
done for numerous studies in the USA. Many studies (mostly from high income countries) 
have substantiated the theory of presenteeism, though the means to measure it are all 
connected with more or less serious methodological challenges.  
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The estimates of the costs and benefits of the interventions included in the model may only 
be validated in a prospective study, though the estimates of effectiveness of the malaria 
interventions are documented by countless studies also from Ghana. The effectiveness 
values of the heath risk assessment interventions proposed by the model are set at very 
conservative values, due to lack of context specific literature to validate them. Again, the 
need for a prospective study in this area should not be underestimated.  
3.8 Assumptions 
The model for estimating the burden of disease faced by an employee population is based 
on numerous assumptions, due to lack of context specific data. In general, the model relies 
on the Ghana national epidemiological data available from the GHS, the NHIS, and the 
WHO. These have been selected as far as available to reflect the urban, adult population 
disaggregated by sex. The statistics used by the NHIS manual24 have been used to estimate 
the relative proportion of outpatient morbidity to inpatient morbidity. 
The same manual has been used to estimate the number of sick days due to outpatient 
morbidity based on the disease specific average length of inpatient stays in hospital. The 
outpatient average duration of illness, derived as a default proportion of 110% of the inpatient 
average stay in hospital has been assumed to equal the number of sick days for each case 
of each disease or condition. There is a further option to use the limited number of disease 
specific average durations of episode of illness available from the authors25 of the Global 
Burden of Disease programme, which provide somewhat higher estimates than the other 
method. These BoD estimates are based on statistics for sub-Saharan Africa. 
The presenteeism estimates have been (very) conservatively estimated to be 25% of the 
calculated sick days for each disease and condition. The presenteeism estimated to be 
attributable to the presence of risk factors is calculated based on Ghana national prevalence 
data, some of which is specific for the urban civil service population of Accra, which is very 
similar to the target populations of employees. The estimates of these extra days of 
presenteeism due to the presence of risk factors is based on the Goetzel et al 200921 study 
of Novartis employees in the USA. 
The cost calculation of the burden of disease estimate made by the model is based simply on 
the average gross salary cost of a work day, which is employer specific and can be provided 
in the input sheet of the model. The default values reflect the GRA-VAT data set for 2010, 
adjusted to a round thousand total population. The death benefit has been assumed to be six 
months' salary which has been used to calculate average yearly days lost for each disease 
based on the mortality rates defined above. This averaging is a way of annualising the costs 
of these days due to death, which in reality are all or nothing propositions. 
The example inputs made in the interventions, costs and benefits screen are based on 
studies of the cost and effectiveness of malaria interventions from Africa and otherwise are 
estimates deemed to be plausible by the authors of this study pending actual revision by the 
user (health risk assessment, check-up). The costs have been annualised by simply dividing 
the investment needed in the first year by the expected duration of the intervention. The 
benefits have also been estimated as an annual reduction of incidence and mortality with the 
respective reduction in work days lost valued as described above.  
Finally, the model does not explicitly include examples of treatment interventions, due mostly 
to the situation that treatment costs have largely been externalized through NHIS enrolment 
of employees since 2011. As well, employers are not well positioned to estimate the benefits 
(effectiveness) of treatment interventions, though they could consult a public health expert for 
advice.  
There was discussion of the implementation of a top-up healthcare insurance to cover the 
employees for most of what the NHIS/GHS will not cover free-of-charge. The costs of 
insurance premiums have also been ignored in the context of this study, as being yearly 
costs independent of any benefit these may derive.  
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3.9 Scope and limitations 
The perspective of employer has very broad ranging effects on the scope of the model and 
its use. This perspective precludes the estimation of costs and benefits which may accrue to 
the employees directly, such as transport costs to health facilities, an increase in wellbeing or 
a reduction in sickness suffered for themselves or their children (use of ITNs or IRS), 
secured incomes for their families through a reduction in deaths and disabilities, etc.  
There are also many societal aspects which have been ignored, but could certainly be 
significant, such as the multiplier effect of well-informed employees concerning health risk 
reduction, being role models in the use of bed nets or internal residual spraying to reduce the 
malaria incidence or the benefits of being enrolled in the NHIS, to name a few examples. The 
benefits to society in this specific case of a healthier GRA could result in higher tax incomes 
for the benefit of the entire country, or better water supply due to healthier, more productive 
GWCL/AVRL workforces.  
The effects of healthier workforces in these target populations may also affect the resource 
flows and allocations of the GHS and other healthcare facilities in the catchment areas 
responsible for the GRA/GCNet and GWCL/AVRL employees. This may be particularly 
interesting if a noticeable shift from treatment to preventive interventions would be 
established.  
Further, the study and the model focussed on providing a user-friendly tool for informing 
investment decisions in the health and well-being of an employer's staff. The tool is based on 
easily collectible and understandable data (for non-scientists), and tries to avoid the blackbox 
syndrome of calculating burden of disease by rigid scientific methodologies.  
This applies, for example, to assumptions made for the model, to base the "cost" of the 
productivity losses on the simply calculable average salary cost per work day. There are 
more elaborate estimates of lost productivity in use, such as the so-called Human Capital 
(HC) method, which estimates the actual wage cost of the lost hours and days of the absent 
employee for as long as the employee is absent. For short term absences the model 
estimates would largely agree with the HC estimates. In the case of long-term disability or 
death, the model caps the losses to the six-month salary death benefit amount and the HC 
method would continue to add the costs well into the future. "This human-capital method has 
been criticized as calculating potential rather than actual productivity costs, leading to 
unrealistically high estimates of productivity costs. In particular, it ignores the possibility of 
replacement of long-term absentees..."31 
The friction cost (FC) method, an alternative suggested in the literature32 33, is proposed by 
some as a better measure of lost production costs from a societal perspective, and assumes 
that an absent employee will be replaced from within the organisation or by hiring a new 
employee and that the cost is therefore limited to the period until the employer is replaced. 
Both the HC and the FC methods require more explicit data and can be used when 
conducting prospective economic evaluations, in which each case is considered individually.  
The model has been purposely kept simple and estimates the productivity losses as the 
wage costs of the forecasted days lost based on the model's epidemiological profile for the 
employee populations.   
The underlying emphasis on making conservative estimates of burden of disease, with 
equally conservative estimates of intervention costs and benefits, with the option to 
adjust according to the specific context should enhance the acceptance and use of the tool. 
This will in turn, should reflect on the quality of investment decisions made by employers in 
the interventions of future EWPs. 
One crucial limitation was the lack of required data requested for the analysis of historical 
productivity loss indicator data. This was mostly explained by the lack of centralized and 
digitalized record keeping both for financial information and for human resources information. 
These were often kept at lower than department level in the GRA and many of the indicators 
such as sick leave days were not collated at department or agency level. It was mentioned 
that this was soon to change with the restructuring of the GRA and the implementation of 
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digitalized record keeping at agency level. This holds promise for the future ability to gather 
needed data more easily and reliably than was possible for this study of historical data. 
3.10 Sensitivity analysis 
The model has been designed to permit "what if" analysis by changing inputs and scaling 
factors for the many variables which are used to calculate the burden of disease in terms of 
days lost and the cost of these days to the employer. This was necessary due to the paucity 
of epidemiological data specific for the target population(s), but also the lack of information 
about the relation between sickness and loss of productivity lead to substantial uncertainties 
in the predicted outcomes. The model implementation therefore supports the end user in 
performing explorative sensitivity analyses to study the effect of varying assumptions about 
the values of different scaling factors used in the model algorithms. 
 
The following example illustrates such an explorative analysis for two of the model 
parameters: selected model endpoints are expressed as function of the following inputs:  
 
• k , which scales lost productivity due to presenteeism as a function of the predicted 
absence days caused by morbidity, and is the scaling factor which is arguably most 
difficult to calibrate against historical data.  
• m , which calculates the number of days away from work per episode using a duration 
proxy.  
 
The base assumption used in the analysis puts the value of k at 25%, and considers 50% 
and 200% as alternatives. Similarly, m is studied under its base assumption value (1.1) 
relative to admission days, and two alternatives (1.0,1,5). The predictions of the resulting 
loss of productivity, consequent cost for the employer, as well as the predicted cost-benefit 
ratio of a possible intervention (MAL-1) are shown in the table below:  
 
Scale Factor 
k : 
Presenteeism 
Scale Factor 
m : 
Duration of 
Episodes 
Total Working 
Days Lost 
Total Cost 
[GHS] 
Cost-benefit 
Ratio: MAL-1 
1.0 1824 126’087 0.9 
1.1 1913 132’245 0.82 
 
25% 
1.5 2270 156’878 0.6 
1.0 2000 138’279 0.76 
1.1 2107 145’656 0.69 
 
50% 
1.5 2534 175’166 0.5 
1.0 3059 211’431 0.38 
1.1 3271 226’123 0.35 
 
200% 
1.5 4121 284’893 0.25 
Table 6: Relationship between the assumed magnitude of presenteeism, duration of absence 
periods, and various model endpoints. (Parameter values in bold indicate baseline 
assumptions.)  
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4 Results 
4.1 WPP/EWP historical data 
As explained previously in this report, the data which were requested to permit a visible 
comparison over time of productivity loss indicators on the one hand, and the investments 
made in the WPP/EWP on the other were not made available in sufficient completeness or 
quality to facilitate any meaningful analysis. The data sets which were the most complete, as 
mentioned above were those for the VAT department of the GRA for the years 2007-2010. 
Below is a graphical presentation of the data: 
 
VAT
0
100
200
300
400
500
600
2005 2006 2007 2008 2009 2010 2011
G
H
S
, 
th
o
u
sa
n
d
s
1
10
100
1'000
10'000
Year
N
u
m
b
e
r,
 l
o
g
Annual medical expenses for staff,  in GHS Annual staff strength
Annual # of claims made Annual # of sick leave days
Annual # of staff turnovers Annual # of compassionate leave days
 
Figure 1: WPP/EWP historical data. 
It is evident from the graph that there can be no conclusions drawn about the effect of the 
investments in WPP/EWP during this same time period in terms of the productivity loss 
indicators represented here. It is not possible to make any statement about how long after an 
investment that one may be able to observe which effect, for example.  
A historical comparison of burden of disease costs to employers against investments made 
in WPP/EWP must be acknowledged to be methodologically questionable. The lack of 
random sampling from target and control populations renders any significance testing 
impossible. Such comparisons cannot be used to validate any cause and effect relationship 
which may seem observable. These shortcomings may best be addressed in a 
methodologically stringent prospective study of adequate duration. 
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4.2 Model forecasts 
4.2.1 Minimal fine-tuning of the model was necessary  
The model is a novel attempt to collect epidemiological evidence of incidence of disease and 
prevalence of risk factors which may be applied to the target populations of employees and 
convert these burdens of disease into measures of productivity losses in terms of work days 
lost, which in turn can be converted into a measure of monetary loss based on the cost of a 
work day. The model attempts to use units of measurement which are intuitively 
understandable for the target employer/user. These have been kept purposely as broadly 
understandable as possible, to avoid the "blackbox" syndrome which could prevent the tool 
from being utilised by the employers. 
The tool allows each of the elements to be adjusted to reflect actual contexts prevailing 
within a particular group of employees. For our analysis, these values have been left 
unchanged to reflect the national Ghanaian epidemiological profile for urban adult 
populations disaggregated according to sex. The model estimates based on these estimates 
of incidence of disease and prevalence of risk factors compared well in terms of overall work 
days lost due to sickness and also in terms of days paid out as death benefits when 
compared to the VAT historical data for the years 2007 to 2010.  
The model was calibrated on the basis of this data by adjusting the factor used to estimate 
the number of outpatient sick days as proportion of the average length of stay for the same 
disease in hospital. The factor of 110% served well to make overall estimates congruent with 
the historical data provided. (The assumption being made here is that for every outpatient 
case of a disease the number of days sick is equal to 110% of the reported average stay in 
hospital for an inpatient case of the same disease.) 
The added value of the model is in providing an evidence-based explanation for these lost 
productive days in accordance with the expected disease profile of the employee population.  
4.2.2 Gender-related deviations?  
The model estimated surprisingly accurately the total number of sick and death benefit days 
for the average 2007-2010 VAT population. There were however, surprising results when the 
estimates were considered separately by sex. The model overestimated the total days sick 
days due to morbidity for male employees by a factor of 180% and the overall sick days plus 
death benefit days for male employees by a factor of 141%. On the other hand, the model 
underestimated the total sick days due to morbidity for female employees to be only 41% of 
the actually reported days and underestimated the total sick days plus death benefit days for 
female employees to be only 52% of the actually reported days. 
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Employees from: VAT VAT VAT VAT VAT 
Year 2007 2008 2009 2010 Average 
Number of male employees 818 820 829 810 819 
Number of female employees 214 249 264 258 246 
Number of working days per year 217 217 217 217 217 
Death Benefit (proportion of working days 
per year) 0.5 0.5 0.5 0.5 0.5 
      
Actually reported data      
Sick days morbidity M&F 825 860 897 812 849 
Sick days morbidity M 227 370 451 365 353 
Sick days morbidity F 598 490 446 447 495 
Number of Staff turnovers due to 
sickness, disability, death 4 4 2 6 4 
Number of Staff turnovers M 4 3 2 4 3 
Number of Staff turnovers F 0 1 0 2 1 
Work days lost due to staff turnovers M&F 434 434 217 651 434 
Work days lost due to staff turnovers M 434 326 217 434 353 
Work days lost due to staff turnovers F 0 109 0 217 81 
Total work days lost (morbidity and 
turnovers) M&F 1259 1294 1114 1463 1283 
Total work days lost (morbidity and 
turnovers) M 661 696 668 799 706 
Total work days lost (morbidity and 
turnovers) F 598 599 446 664 577 
      
Model estimates      
Sick days morbidity M&F 809.17 839.38 858.63 839.00 836.55 
Sick days morbidity M 633.92 635.47 642.44 627.72 634.89 
Sick days morbidity F 175.25 203.91 216.19 211.28 201.66 
Sick days death benefits M&F 447.08 462.11 472.15 461.34 460.67 
Sick days death benefits M 360.56 361.44 365.41 357.03 361.11 
Sick days death benefits F 86.52 100.67 106.74 104.31 99.56 
Total work days lost (morbidity and 
turnovers) M&F 1'256.25 1'301.49 1'330.78 1'300.34 1'297.22 
Total work days lost (morbidity and 
turnovers) M 994.48 996.91 1'007.85 984.75 996.00 
Total work days lost (morbidity and 
turnovers) F 261.77 304.58 322.93 315.59 301.22 
      
Comparison estimate/actual      
Sick days morbidity M&F 98.1% 97.6% 95.7% 103.3% 98.6% 
Sick days morbidity M 279.3% 171.7% 142.4% 172.0% 179.7% 
Sick days morbidity F 29.3% 41.6% 48.5% 47.3% 40.7% 
Work days lost due to staff turnovers M&F 103.0% 106.5% 217.6% 70.9% 106.1% 
Work days lost due to staff turnovers M 83.1% 111.0% 168.4% 82.3% 102.4% 
Work days lost due to staff turnovers F #DIV/0! 92.8% #DIV/0! 48.1% 122.3% 
Total work days lost (morbidity and 
turnovers) M&F 99.8% 100.6% 119.5% 88.9% 101.1% 
Total work days lost (morbidity and 
turnovers) M 150.5% 143.3% 150.9% 123.2% 141.1% 
Total work days lost (morbidity and 
turnovers) F 43.8% 50.9% 72.4% 47.5% 52.2% 
Table 7: Gender-related deviations? 
These surprising results would need to be explored in terms of the accuracy of the gathered 
data and whether the model has missed to take into account context related differences in 
behaviour in terms of taking sick leave between men and women. The results suggest that 
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men take about half as much sick leave, and that the women take about 2-1/2 times as much 
as the model suggests they should.  
4.2.3 Presenteeism 
The inclusion of estimates for presenteeism based on the same disease profile and the 
prevalent health risk factors has added a further dimension to the issue of productivity 
losses. The insight gained by the employer into possible causes of the reported absentee 
days and the "unseen" productivity losses due to presenteeism inform decision-making about 
investments in interventions as part of a EWP.   
The estimates of productive days lost due to presenteeism as a proportion of sick leave days 
are very conservative. The additional presenteesim days included due to the presence of 
health risk factors are also calculated conservatively as the additional lost productive days 
estimated in the study of Novartis employees over those presenteesim days found where 
these risk factors were not present.  
The estimates of presenteeism could not be verified from the historical data and would need 
to be verified in a prospective study using one of the many presenteeism survey tools which 
have been developed and tested in depth in the USA. 
4.2.4 Malaria, hypertension, HIV/AIDS 
As mentioned earlier in section three, the model suggests, for example, that almost one 
quarter of the productivity losses can be explained by the incidence of malaria in the 
employee population and the costs of these lost days also provide the employer with a 
conservative estimate of the magnitude of the malaria problem in financial terms. The model 
proposes that over half of the productivity losses measured in terms of work days lost can be 
explained by the incidence of non-acute diseases and the prevalence of health risk factors. 
Acute diseases account for most of the rest of the lost productive days: 
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VAT Average 2007-2010 Population   
     
     
Disease / Risk Factor 
Percent of 
Productivity 
losses  Disease / Risk Factor 
Percent of 
Productivity 
losses 
Malaria 24.99%  Acute diseases 22.91% 
     Infection upper respiratory tract 4.20% 
Non-acute diseases & risk 
factors 50.98%  Diarrhoeal diseases 4.42% 
Hypertension 12.42%  Acute eye infections 2.71% 
HIV/AIDS 7.34%  Home/occupational injuries 2.38% 
Skin diseases 5.87%  Road traffic injuries 1.94% 
Obesity 5.65%  Tropical-cluster diseases 1.39% 
Physical Inactivity 3.28%  Typhoid fever 1.03% 
Diabetes Mellitus 3.04%  Violence 1.10% 
Tuberculosis 3.54%  Other unintentional injuries 1.00% 
Intestinal worms 1.26%  Pneumonia 0.73% 
Cerebrovascular disease 1.46%  Lower respiratory infections 0.84% 
Anaemia 1.15%  Acute ear infection 0.68% 
Ischaemic heart disease 1.34%  Other oral conditions 0.33% 
Alcohol 0.97%    
Diet 0.18%  Total  98.72% 
Breast cancer 0.16%    
Table 8: Productivity losses in percent per disease/risk factor for VAT Average 2007-2010 
Population. 
These estimates are obviously very sensitive to the proportions of male and female 
employees, given their differing disease profiles and are here shown above as a total of both 
populations. The sex-disaggregated estimates are also provided by the model for each of the 
contributing factors: sick days due to morbidity, presenteeism due to sickness, presenteeism 
due to the prevalent health risk factors, and days lost due to employee turnovers (death 
benefits). Below is an example for sick leave days: 
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Calculated Annual Work Days Lost (Sick leave) 
    
VAT average population 2007 - 2010  
    
Disease specific number of episodes and calculated absence days     
Disease 
Number of 
Episodes 
Male 
Employees 
Hospital 
admissions 
Male 
Employees 
Number of 
Episodes 
Female 
Employees 
Hospital 
admissions 
Female 
Employees 
Absence 
Days 
Male 
Employee 
Absence 
Days 
Female 
Employee 
Total 
Absence 
Days 
Malaria 86.84 0.95 26.75 0.33 305.68 94.59 400.27 
Skin diseases 8.05 0.03 2.42 0.01 73.51 22.10 95.61 
Infection upper 
respiratory tract 13.29 0.03 3.99 0.01 52.63 15.82 68.45 
Acute eye 
infections 4.35 0.01 1.31 0.00 33.94 10.20 44.14 
Diarrhoeal 
diseases 8.05 0.13 2.42 0.04 30.11 9.05 39.16 
Home/occupation
al injuries 4.38 0.08 1.32 0.03 29.90 8.99 38.89 
Hypertension 5.70 0.08 1.71 0.02 26.98 8.11 35.09 
Intestinal worms 3.07 0.03 0.92 0.01 15.85 4.76 20.61 
Anaemia 3.30 0.21 0.99 0.06 14.51 4.36 18.87 
Typhoid fever 1.75 0.00 0.52 0.00 12.87 3.87 16.74 
Pneumonia 1.84 0.15 0.55 0.05 9.33 2.80 12.13 
Road traffic 
injuries 1.75 0.06 0.52 0.02 8.84 2.66 11.49 
Acute ear 
infection 1.84 0.02 0.55 0.01 8.52 2.56 11.07 
Diabetes Mellitus 0.91 0.02 0.27 0.01 8.12 2.44 10.57 
Other oral 
conditions 1.20 0.00 0.36 0.00 4.10 1.23 5.33 
Pregnancy and 
related 
complications 
0.00 0.00 1.18 0.04 0.00 4.95 4.95 
Gynaecological 
conditions 0.00 0.00 0.76 0.04 0.00 3.17 3.17 
Rheumatic and 
joint diseases 3.71 0.00 1.11 0.00 0.00 0.00 0.00 
Dental caries 1.20 0.00 0.36 0.00 0.00 0.00 0.00 
Total 151.23 1.81 48.05 0.66 634.89 201.66 836.55 
Table 9: Calculated Annual Work Days Lost (Sick leave), VAT average population 2007-2010. 
The conversion of these lost days of productivity into financial terms is realised in the model 
by providing the inputs of the numbers of male and female employees, the annual total gross 
salary expenditure for these same employees, the number of working days annually and also 
the factor for calculating the death benefits in case of mortality as a proportion of the annual 
working days. These inputs permit the model to calculate an average cost of a working day. 
This average cost is then used to convert the estimate of lost productive days into a financial 
loss by simple multiplication.   
These losses can be viewed per disease as a total: 
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Costs Contributions of Morbidity, Mortality and Risk 
Factors by Condition 
      
VAT 2010 Population 
      
Total costs [GHS]       
Disease / Risk 
Factor 
Costs 
Morbidity 
Costs 
Presenteeism 
(due to 
morbidity) 
Costs 
Presenteeism 
(due to risk 
factors) 
Costs 
Mortality 
Total Costs 
per 
Disease / 
Risk Factor  
Percent 
of Total 
Costs  
Malaria 28'915.46 7'146.90 n.a. 662.87 36'725.22 24.97% 
Hypertension 2'534.12 624.88 15'094.36 n.a. 18'253.37 12.41% 
HIV/AIDS n.a. n.a. n.a. 10'802.56 10'802.56 7.34% 
Skin diseases 6'904.58 1'720.13 n.a. n.a. 8'624.72 5.86% 
Obesity n.a. n.a. 8'470.70 n.a. 8'470.70 5.76% 
Diarrhoeal 
diseases 2'828.38 695.67 n.a. 2'965.75 6'489.81 4.41% 
Infection upper 
respiratory tract 4'943.16 1'233.26 n.a. n.a. 6'176.41 4.20% 
Tuberculosis n.a. n.a. n.a. 5'154.88 5'154.88 3.50% 
Physical Inactivity n.a. n.a. 4'870.57 n.a. 4'870.57 3.31% 
Tobacco n.a. n.a. 4'815.84 n.a. 4'815.84 3.27% 
Diabetes Mellitus 763.12 186.42 3'510.70 n.a. 4'460.24 3.03% 
Acute eye 
infections 3'188.00 795.82 n.a. n.a. 3'983.81 2.71% 
Home/occupational 
injuries 2'808.74 688.78 n.a. n.a. 3'497.52 2.38% 
Road traffic 
injuries 829.87 199.78 n.a. 1'803.40 2'833.05 1.93% 
Cerebro-vascular 
disease n.a. n.a. n.a. 2'146.37 2'146.37 1.46% 
Tropical-cluster 
diseases n.a. n.a. n.a. 2'025.17 2'025.17 1.38% 
Ischaemic heart 
disease n.a. n.a. n.a. 1'957.06 1'957.06 1.33% 
Intestinal worms 1'488.56 368.05 n.a. n.a. 1'856.61 1.26% 
Anaemia 1'363.08 319.47 n.a. n.a. 1'682.55 1.14% 
Pregnancy and 
related 
complications 
373.54 90.23 n.a. 1'209.80 1'673.58 1.14% 
Violence n.a. n.a. n.a. 1'597.01 1'597.01 1.09% 
Typhoid fever 1'208.73 301.58 n.a. n.a. 1'510.31 1.03% 
Other unintentional 
injuries n.a. n.a. n.a. 1'456.75 1'456.75 0.99% 
Alcohol n.a. n.a. 1'428.29 n.a. 1'428.29 0.97% 
Lower respiratory 
infections n.a. n.a. n.a. 1'213.11 1'213.11 0.82% 
Pneumonia 875.98 200.79 n.a. n.a. 1'076.76 0.73% 
Acute ear infection 799.81 197.76 n.a. n.a. 997.56 0.68% 
Other oral 
conditions 385.27 96.25 n.a. n.a. 481.52 0.33% 
Gynaecological 
conditions 239.21 56.65 n.a. n.a. 295.86 0.20% 
Diet n.a. n.a. 273.35 n.a. 273.35 0.19% 
Breast cancer n.a. n.a. n.a. 244.76 244.76 0.17% 
Rheumatic and 
joint diseases n.a. n.a. n.a. n.a. 0.00 0.00% 
Dental caries n.a. n.a. n.a. n.a. 0.00 0.00% 
Total Costs 60'449.61 14'922.42 38'463.83 33'239.50 147'075.34 100% 
Table 10: Costs Contributions of Morbidity, Mortality and Risk Factors by Condition, VAT 2010 
population.  
The sex-disaggregated cost estimates are also provided by the model for each of the 
contributing factors: sick days due to morbidity, presenteeism due to sickness, presenteeism 
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due to the prevalent health risk factors, and days lost due to employee turnovers (death 
benefits). Below is an example for sick leave days: 
 
Costs due to Absence Days (Sickness) 
VAT 2010 Population 
Disease costs due to absence days [GHS] 
Disease 
Costs Male 
Employees 
Costs Female 
Employees 
Total 
Costs 
Malaria 21'775.35 7'140.10 28'915.46 
Skin diseases 5'236.62 1'667.96 6'904.58 
Infection upper respiratory tract 3'749.02 1'194.13 4'943.16 
Acute eye infections 2'417.86 770.13 3'188.00 
Diarrhoeal diseases 2'145.12 683.26 2'828.38 
Home/occupational injuries 2'130.22 678.52 2'808.74 
Hypertension 1'921.94 612.18 2'534.12 
Intestinal worms 1'128.96 359.60 1'488.56 
Anaemia 1'033.79 329.28 1'363.08 
Typhoid fever 916.73 292.00 1'208.73 
Pneumonia 664.36 211.61 875.98 
Road traffic injuries 629.40 200.47 829.87 
Acute ear infection 606.59 193.21 799.81 
Diabetes Mellitus 578.77 184.35 763.12 
Other oral conditions 292.20 93.07 385.27 
Pregnancy and related 
complications 0.00 373.54 373.54 
Gynaecological conditions 0.00 239.21 239.21 
Rheumatic and joint diseases 0.00 0.00 0.00 
Dental caries 0.00 0.00 0.00 
Total costs 45'226.97 15'222.64 60'449.61 
Table 11: Costs due to Absence Days (Sickness), VAT 2010 population.  
4.3 Interventions, costs and benefits 
The model sorts the top sources of productivity losses estimated into the three categories 
mentioned earlier in order to explore possible interventions which the employer can 
undertake as part of the EWP. For all of the categories, it is possible to add own 
interventions for consideration. 
4.3.1 Category one:  malaria 
The category of malaria offers two preventive interventions: insecticide treated bednets 
(long-lasting insecticide impregnated bednets LLIN) and internal residual spraying and a 
combination of both. For each intervention there are estimates of cost per employee, 
effectiveness in terms of malaria incidence and fatality prevented by these interventions and 
the related work days saved, and the value of these days saved in terms of the salary 
expenditure saved. This information is then used to calculate a cost benefit ratio and the net 
benefit.  
Swiss TPH | GTZ Ghana EWP CBA 
38 
It is possible to modify all of the variables according to local context in order to calculate a 
more accurate CBR and net benefit. For example, it may be possible to obtain LLIN from the 
global Roll Back Malaria programme for free. In this case, the annual costs per employee 
could be reduced by the costs of the nets and only programmatic costs need be estimated. 
4.3.2 Category two: non-acute diseases and prevalent risk factors 
The second category of non-acute diseases and prevalent risk factors, which the model 
suggests to be responsible for over half of the productivity losses offers little in the way of 
interventions which the employer could offer as this category has many different elements 
which alone are relatively "inexpensive" and for which preventive measures are many-fold. 
The model suggests that the most obvious first step in dealing with these diseases and 
conditions is to encourage each employee to have a regular health check-up. In the context 
then of a doctor-patient relationship it is assumed that each employee will become aware of 
any need for treatment or for reducing health risks.  
The employer could offer incentives to encourage this, and could also arrange for in-house 
health checks to bring the opportunity closer to the employees on a regular basis. The 
calculations of a CBR and net benefit for these are highly context related and estimates of 
the effectiveness of regular check-ups are difficult to make. The model allows for "what-if" 
parameter changes to explore when the CBR and net benefits become favourable to the 
employer.  
 
Here is an example in summary form of the results of the CBA for suggested interventions: 
 
Disease 
/ Risk 
Factor 
Cost of 
Problem 
Percent 
of 
Proble
m 
Intervent
ion Type 
Annual 
Cost per 
Employee 
[GHS] 
Annual 
Cost of 
Interventi
on [GHS] 
Annual 
Benefit 
[GHS] 
Cost / 
Benefit 
Ratio 
Net 
Benefit 
[GHS] 
Malaria 32'764.30 24.78% 
MAL-1 :  
Insecticid
e-treated 
bed nets 
(ITN) 13.33 13'330.00 16'203.51 0.8227 2'873.51 
   
MAL-3 :  
Indoor 
residual 
spraying 
(IRS) 18.05 18'050.00 16'203.51 1.1140 -1'846.49 
   
Both 
MAL-1 
and 
MAL-3 31.38 31'380.00 23'012.56 1.3636 -8'367.44 
         
Non-
acute 
disease
s & risk 
factors 67'517.88 51.06% 
Health 
risk 
assessm
ent (in-
house) 19.30 19'300.00 6'751.79 2.8585 
-
12'548.21 
   
Health 
risk 
assessm
ent (go to 
doctor) 35.50 35'500.00 6'751.79 5.2579 
-
28'748.21 
Table 12: An example in summary form of the results of the CBA for suggested interventions.  
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4.3.3 Category three: acute diseases 
The third and final category of acute diseases, which the model suggests to account for 
most of the rest (about one quarter) of productivity losses is one in which the employer can 
do very little and indeed need not do much as the employees will likely be self-motivated by 
the acuteness of the condition to seek appropriate care in a timely manner. The model does 
not suggest any specific interventions, but does allow the user to add interventions also for 
this category. 
4.4 Positive net benefits? 
With reference to the study's research hypothesis, there are indeed positive net benefits to 
be realised by the employer in investing in interventions to preserve and improve the health 
status and well-being of the employees. The examples shown are based on very 
conservative estimates of costs and benefits. For many of the interventions, it may be 
possible to reduce the annual costs per employee if there are national or global programmes 
which may provide material or programmatic support, such as for malaria, HIV/AIDS, or 
maternity conditions.  
Also, the estimates of effectiveness of the health risk assessments are also very 
conservative, due to the difficulty, for example, to estimate rates of participation, which 
diseases and conditions will be diagnosed and treated, as well as the time-frame in which 
each of these treatments will result in noticeable improvements in productivity.  
Even where there may be negative net benefits, given the narrow perspective of the study, 
these interventions may still be worthwhile for the employer to invest as the benefits which 
may accrue to the employee, families and community may be substantial and provide a way 
for an employer to enhance its status as an attractive employer and a good corporate citizen. 
4.5 What-if...? 
As all of these input variable are highly context related, the model permits adjustment as 
needed, as better information becomes available. The model provides moreover a very 
useful tool to analyse the various options by conducting what-if analysis by varying the inputs 
accordingly. The calculation of the expected CBR and net benefit inform the employer of the 
ranges for each intervention which still result in a positive result.  
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5 Conclusions and Recommendations 
5.1 Summary  
The study of the employee wellbeing programmes supported by the GIZ in Ghana has 
proven to be a challenge in terms of collecting the data needed, and more so to reconcile to 
the requirements of a scientific research methodology with the pragmatic needs of employers 
and the conditions prevailing in the context of Ghana. The model, which was developed to 
provide employers with evidence-based estimates of productivity losses measured in simple 
terms of work days lost, has attempted to bridge the gap between these. 
The model makes a novel attempt to convert epidemiological data (population incidence and 
prevalence rates) into measures which an employer can understand related to the population 
of the employees. The model provides a forecast of which diseases and conditions are likely 
to cause how many lost production days in order to inform investment decisions aimed at 
improving the health and wellbeing of its employees. This is a worthwhile undertaking in own 
stead, as this provides a clear picture of the most costly "problems". The model goes further 
and suggests interventions which guide the employer to also be able to estimate what the 
organisation can expect to gain in terms of improved productivity through implementing these 
interventions.  
The model has, in the authors' opinion, succeeded in putting the knowledge of the 
epidemiologist at the disposal of employers in a format which is intuitive and helps to explain 
the causes of productivity losses without the need to undertake an expensive large scale 
study of employees directly.  
The main results of the model are the estimates that employers (employees) of the GIZ 
supported EWP will be confronted, first and foremost, by the effects of malaria (about a 
quarter of the problem) and hypertension (about one eighth). The model suggests that over 
half of the productivity losses can be expected to come from the category of non-acute 
diseases and prevalent health risk factors. Both of these first two categories provide an 
employer with some room to act, through preventive interventions. The final category, which 
explains most of the remaining forecasted productivity losses, offers an employer basically 
no opportunity to act.  
The flexibility of the model allows the user to perform unlimited "what-if?" sensitivity analysis 
and to adjust the model inputs according to actual conditions prevailing. Still, the statistics 
behind the model are tailored clearly for the urban, adult population of Ghana and as far as 
possible to reflect the civil servant profile. These would need to be replaced by actual context 
data to enable usage outside of the intended context. 
5.2 Discussion  
The study results are based on a number of assumptions and on historical data which are 
both cause for considerable uncertainty. In most of the assumptions, conservative, plausible 
choices were made in order to err, if so, on the side of underestimation.  
 
The limiting of the measures of productivity losses to sick days and presenteeism valued at 
the cost of an average day's salary also lead to conservative estimates of losses and also of 
benefits from the interventions suggested. The accuracy of the model to explain the causes 
of productivity losses could only be verified by further research. The employees could be 
studied to establish the actual disease profile in comparison to the estimate made based on 
the Ghana national statistics.  
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A prospective study could strengthen the accuracy of recording of sick days, and could verify 
through presenteeism surveys, as are conducted in the USA, the estimates of lost 
productivity over and above actual sick days recorded, though the use of such a survey tool 
may be biased due to cultural mistrust of admitting on the job productivity losses. 
 
The limitations of the perspective of the employer in this study also underline the 
conservative estimates of the costs of the BoD and the benefits to be derived through 
targeted interventions. The full extent of these could be established in a broader study of the 
costs and benefits with the inclusion of the perspectives of the employees, and their families, 
and also from the societal perspective. The latter would underline the employer's case for 
good corporate citizenship. 
 
The model provides the employer with the more specific evidence of the health profile and 
needs of the employees and allows the employer to tailor the design of the EWP accordingly.  
 
The tool also sensitizes the employers to understanding and using epidemiological 
information in an intuitive way, paving the way for revising the interventions offered according 
to changes in the health profile of the employee population. One area which hardly is 
observable in the currently kept statistics of morbidity in Ghana (and Africa in general) is that 
of mental health. One example is the estimated prevalence of attention deficit hyperactivity 
disorder globally of 3-5% of the global adult population as evidenced by a recent WHO 10 
country study by de Graaf et al34 . This disease alone could have a large impact on 
presenteeism of any workforce, but does not show up in the morbidity statistics in Africa. 
5.3 Recommendations  
The study and the unique model developed open the way to an evidence based estimation of 
the health profile of an employee population without the need for conducting an expensive 
study of the employee population or a sample thereof in order to inform employers of cost-
effective interventions they can offer to their employees to improve their health status and 
their productivity on the job. It is recommended to validate the model and refine it through 
use by the employers of the GIZ supported EWPs within the framework of a prospective 
study. This would help to validate the model, to refine the algorithms behind the model and to 
improve the utility and acceptance of the model for use by employers.  
 
Swiss TPH | GTZ Ghana EWP CBA 
42 
6 References 
                                                
1
 http://www.gtz.de/en/weltweit/afrika/ghana/32800.htm  
2
 de-Graft AA. Ghana's neglected chronic disease epidemic: a developmental challenge. 
Ghana Med J 2007 Dec;41(4):154-9. 
3
 WHO. World Malaria Report: Ghana. available from: http://www.who.int/countries/gha/en/ . 
2009.   [accessed 4/01/2011] 
4
 WHO. WHO Global Health Observatory. available from: http://apps.who.int/ghodata/ . 2009.          
[accessed 4/01/2011] 
5
 UNAIDS & WHO. Epidemiological Fact Sheet on HIV and AIDS: Core data on epidemiology 
and response: Ghana. available from: http://www.who.int/countries/gha/en/ . 2008. [accessed 
4/01/2011] 
6
 Bosu WK. Epidemic of hypertension in Ghana: a systematic review. BMC Public Health 
2010;10:418. 
7
 Addo J, Smeeth L, Leon DA. Prevalence, detection, management, and control of 
hypertension in Ghanaian civil servants. Ethn Dis 2008;18(4):505-11. 
8
 WHO. WHO Global Infobase - data for saving lives: country profiles. available from: 
https://apps.who.int/infobase/CountryProfiles.aspx. 2010. [accessed 4/01/2011] 
9
 Abubakari AR, Bhopal RS. Systematic review on the prevalence of diabetes, 
overweight/obesity and physical inactivity in Ghanaians and Nigerians. Public Health 2008 
Feb;122(2):173-82. 
10
 http://www.nhis.gov.gh/_Uploads/dbsAttachedFiles/Slide1.JPG (accessed 14.01.2011) 
11
 GCNet was founded in the year 2000 to develop and implement a computerized system for 
the validation and forwarding of trade and customs documentation. The main stakeholder of 
GCNet is Societé Generale de Surveillance (SGS) SA of Switzerland (60%). Other 
shareholders are Customs Excise and Preventive Services (20%), Ghana Shippers Council 
(GSC) (10%), Ghana Commercial Bank (GCB) (5%) and ECOBANK Ghana (5%). GCNet is 
a private institution but because of the shareholders structure and the nature of the contract 
is bound by governmental interest. GCNet automated the Ghanaian Customs Services in the 
year 2004 and uses computerized systems for the administration of customs documents for 
clearing of goods at the various entry points as well as the controlling of the related financial 
transactions. The Company also delivers trade facilitation services in countries such as 
Nigeria, Cote D’ Ivoire, Cameroun and Madagascar within Africa. 
12
 Zungu LI, Setswe KG. An integrated approach to the prevention and promotion of health in 
the workplace: A review from international experience. South African Family Practice 
2007;49(6):6-9. 
13
 Pelletier KR. A review and analysis of the clinical and cost-effectiveness studies of 
comprehensive health promotion and disease management programs at the worksite: update 
VII 2004-2008. J Occup Environ Med 2009;51(7):822-37. 
14
 Baicker K, Cutler D, Song ZR. Workplace Wellbeing Programs Can Generate Savings. 
Health Aff. 2010;29(2). 
15
 Kirsten W. Making the Link between Health and Productivity at the Workplace -A Global 
Perspective. Ind. Health 2010;48(3):251-55. 
16
 Chapman LS. Presenteeism and its role in worksite health promotion. American Journal of 
Health Promotion 2005;19(4):1-8. 
Swiss TPH | GTZ Ghana EWP CBA 
43 
                                                                                                                                                   
17
 Hemp P. Harvard Business Review: Presenteeism: At work but out of it, 2004, Vol.82, 
no.10, p.49-58.  
18
 Sainsbury Centre for Mental Health 2007 Policy Paper No. 8 Mental Health at Work: 
Developing the Business Case. 
19
 Goetzel RZ, Pronk NP. Worksite Health Promotion: How Much Do We Really Know About 
What Works? American journal of preventive medicine 2010;38(2):S223-S25. 
20
 O’Donnell M, Bishop C, Kaplan K. Benchmarking best practices in workplace health 
promotion. Art Health Promot 1997;1(1):1– 8. 
21
 Goetzel RZ, Carls GS, Wang S, Kelly E, Mauceri E, Columbus D, et al. The Relationship 
Between Modifiable Health Risk Factors and Medical Expenditures, Absenteeism, Short-
Term Disability, and Presenteeism Among Employees at Novartis. Journal of Occupational 
and Environmental Medicine 2009;51(4):487-99. 
22
 The Health Sector in Ghana Facts and Figures 2009 
http://www.ghanahealthservice.org/includes/upload/publications/Facts and Figures 2009.pdf 
23
 http://www.who.int/choice/en/ 
24
 National Health Insurance Scheme Tariff and Benefits Package Operation Manual 2008. 
25
 Murray, Christopher J.L., Alan D. Lopez, Global Health Statistics: a compendium of 
incidence, prevalence and mortality estimates for over 200 conditions, WHO 1996. 
26
 Personal communication with Dr. Adriana Ignea 
27
 For a complete list of services provided and exempted by the National Health Insurance 
Scheme NHIS Benefits Package  see: 
http://www.nhis.gov.gh/?CategoryID=158&ArticleID=120 
28
 Morel CM, Lauer JA, Evans DB. Cost effectiveness analysis of strategies to combat 
malaria in developing countries. BMJ 2005;331(7528):1299. 
29
 Kolaczinski J, Kolaczinski K, Kyabayinze D, Strachan D, Temperley M, Wijayanandana N, 
et al. Costs and effects of two public sector delivery channels for long-lasting insecticidal nets 
in Uganda. Malaria Journal 2010;9(1):102. 
30
 Indoor Residual Spraying (IRS) for Malaria Control Indefinite Quantity Contract (IQC) Task 
Order 1 (TO1) Analysis of 2008 Expenditures in Five IRS TO1 Countries: 
http://www.fightingmalaria.gov/resources/reports/irs_iqc08.pdf  
31
 Brouwer WBF, Koopmanschap MA. The Friction-Cost Method: Replacement for Nothing 
and Leisure for Free? Pharmacoeconomics 2005;23(2):105-11. 
32
 Birnbaum H. Friction-Cost Method as an Alternative to the Human-Capital Approach in 
Calculating Indirect Costs. Pharmacoeconomics 2005;23(2):103-04. 
33 van den Hout WB. The value of productivity: human-capital versus friction-cost method. 
Annals of the Rheumatic Diseases 2010;69(Suppl 1):i89-i91. 
34
 de Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. The 
prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the 
performance of workers: results from the WHO World Mental Health Survey Initiative. 
Occupational and Environmental Medicine 2008;65(12):835-42. 
http://oem.bmj.com/content/65/12/835.full.pdf 
 
Swiss TPH | GTZ Ghana EWP CBA 
44 
7 Appendices, Tables and Charts 
7.1 Appendix 1: Model equations 
7.1.1 Estimation of disease-specific annual number of episodes 
Due to the paucity of data on disease-specific incidence rates, data on outpatient clinic 
attendance was used to approximate incidence rates. Malaria –where most data is available- 
was used as a reference. The disease-specific annual number of episodes iE  (except for the 
special case of malaria mE ) in the target population were calculated as follows: 
 
i
i m i
m
tE c f N
t
= ⋅ ⋅ ⋅  
 
where  
 
:mc Incidence of malaria (per person year at risk) 
:if  Disease-specific scaling factor to adjust for the fact that the target population is a non-
random sample of the Ghanaian population 
:it  Observed contribution of the disease to total outpatient morbidity 
:mt  Observed contribution of malaria to total outpatient morbidity 
:N  Number of employees 
 
For malaria, the annual incidence was directly available 
 
m m mE c f= ⋅  
 
:mf  Scaling factor to adjust for the fact that the target population is a non-random sample of 
the Ghanaian population 
 
This equation makes a number of assumptions: most notable, that national insurance data is 
proportional to target population, and that the treatment seeking probability is similar for 
different diseases. These assumptions can be adjusted by a user of the tool by modifying the 
corresponding disease-specific scaling factors in the “Input parameters” worksheet. 
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7.1.2 Calculation of disease-specific absence days due to sickness 
The model contains two different algorithms for the calculation of the absence days as a 
function of the annual number of episodes of a disease, and the average duration of absence 
due to a disease episode. The first uses the reported average duration of hospitalization due 
to an episode as a proxy. This duration is then scaled to using a scaling factor to calculate 
the number of absence days caused by an episode. The number of absence days per year 
iA is then calculated as 
 
i i i iA h m E= ⋅ ⋅  
 
where  
 
:ih  The disease-specific duration of hospital days of admitted patients 
:im  A disease-specific scaling factor to relate the hospital stay length to the number of days 
absent from work due to a disease episode 
 
 
Where available, the average duration of an episode can also be based alternative data on 
disease duration and severity, e.g. as published in Murray and Lopez (1996) (REF: 
Christopher J.L. Murray & Alan D.Lopez, Global Health Statistics, Harvard University Press, 
1996). The user can enable this alternative algorithm for the calculation of absence days by 
ticking the checkbox “Use disease duration and disability weight” in the “Input Parameters” 
worksheet. Absence days are then calculated as follows: 
 
 if 
0           if 
i i i i i
i i
A l s E w C
A w C
= ⋅ ⋅ >

= ≤
 
 
where 
 
:il  The disease-specific duration of an episode 
:iw  The disease-specific disability during an episode 
:is  A disease-specific scaling factor to map disability to the probability of being absent 
:C  A threshold which determines whether disease episode cause absence days 
7.1.3 Presenteeism (due to morbidity) 
The estimated loss of productivity due to presenteeism iP  is based on the disease-specific 
absence days as a proxy, and calculated as follows 
 
(1 )i i i iP r A k= − ⋅ ⋅  
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where  
 
:ir Disease-specific proportion of cases which are admitted to hospital. 
:ik  A disease-specific scaling factor to relate the lost productivity due to presenteeism to 
absent days 
7.1.4 Estimation of disease-specific annual number of deaths 
The disease-specific annual number of deaths is derived from national disease specific 
mortality rates and the number of employees.  
i i iD g d N= ⋅ ⋅  
 
where  
 
:ig  Disease-specific scaling factor to adjust for the fact that the target population is a non-
random sample of the Ghanaian population 
:id  Disease-specific national mortality rate (per capita) 
:N  Number of employees 
7.1.5 Calculation of disease-specific absence days due to employee turnover 
 
i iT E V D= ⋅ ⋅  
 
where  
 
:E  Death benefit (proportional factor of total working days per year) 
:V  The annual number of working days 
7.1.6 Presenteeism (due to risk factors) 
The estimated number of unproductive days due to extra-morbidity presenteeism iQ   (due to 
the presence of risk factor), is calculated as follows: 
 
i i iQ u p N= ⋅ ⋅  
 
where  
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:iu  Risk factor-specific scaling factor to relate presence of a risk factor to lost productivity 
due to presenteeism 
:ip  Risk factor-specific prevalence 
7.1.7 Calculation of the impact of health interventions and cost-benefit ratio 
The predicted benefit (costs saved) of a health intervention is calculated on the basis the 
consequent reduction in the costs due to disease and risk factors (including the effects of 
presenteeism), and to employee turnover. 
 
( ( 1 2 ) )i i i i i i i iB q rI tCD tCP tCP rM tCM= ⋅ + + + ⋅  
 
where 
 
:iB  Benefit (annual cost savings) due to the intervention 
:iq  Proportion of employees covered by intervention 
:irI  Reduction in disease or risk factor prevalence 
:itCD  Total cost caused by disease 
1 :itCP  Total cost due to presenteeism (morbidity) 
2 :itCP  Total cost due to presenteeism (risk factor) 
:irM  Reduction in mortality 
:itCM  Total cost due to mortality (employee turnover) 
 
The net benefit of a health intervention is calculated as: 
 
i i iCBR B IC= −  
where  
 
:iIC The annual intervention cost 
 
The cost benefit ratio is given by: 
 
i
i
i
ICCBR
B
=  
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7.2 Appendix 2: Excel Tool user guide 
 
The Excel tool implements the model algorithms used to calculate total work days lost and 
costs due to morbidity, mortality and risk factors and provides a set of intervention packages 
which can be applied to various disease categories.  The cost-benefit ratio as well as the net 
benefit is then calculated. 
7.2.1 Excel Settings 
The tool uses Excel-Macros for calculation of results. Make sure that the macro security level 
is set appropriate to allow execution of Macros. 
 
7.2.2 Sections & Navigation 
The tool consists of a workbook structured into various sections: 
 
• Data Sources  
• Input Parameters & Scaling Factors 
• Calculation of predicted work days lost and costs 
• Interventions 
• Epidemiological data, hospital stays, disease duration and disability weights 
• Various information and WHO CHOICE reference sheet 
 
The following screenshot shows the ‘Overview & Navigation’ worksheet listing all available 
worksheets of the various categories: 
 
 
 
 
Using the hyperlinks this worksheet allows for easy navigation inside the whole workbook. 
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7.2.3 Input Parameters 
 
The ‘Input Parameters’ worksheet is divided into different sections which allow the user to 
define input parameters, select options related to calculation algorithms and adjust various 
scaling factors. Changing input parameters and scaling factors will have an immediate 
impact on calculation results of working days lost and costs. 
 
The first section covers input parameters related to employees like the number of 
male/female employees, the total annual salary, number of working days and the death 
benefit proportional factor: 
 
 
 
In the ‘Global Settings’ section the user selects one of the model calculation options: 
• Calculation based upon average days of stay in hospital 
• Calculation based upon disease duration and disability weights 
 
 
  
Three sections of scaling factors related to morbidity, risk factors and mortality allow the user 
to further parameterise calculation of total absence days and costs: 
 
 
 
The user input is validated and an error message is displayed in case the value is not valid. 
When a parameter value is changed from its default value, a flag is displayed to indicate that 
the user is about to perform a sensitivity analysis: 
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7.2.4 Calculation of predicted work days lost 
 
Based on calculation algorithms described in the report in detail, the worksheet ‘Predicted 
Work Days Lost’ contains various tables that give an overview of predicted work days lost 
caused by morbidity, presenteeism and morality. The following screenshots shows the table 
of calculated work days lost due to sickness: 
 
 
 
 
 
For each disease, the number of episodes, hospital admissions and absence days of male 
and female employees are listed. Further tables contain detailed information concerning 
calculated work days lost due to death (employee-turnover), as well as information related to 
presenteeism caused by morbidity and risk factor. 
 
A summary worksheet ‘Days Lost Summary’ provides an overview and summary of total 
work days lost caused by morbidity, mortality and presenteesim: 
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7.2.5 Calculation of costs 
 
On basis of calculated predicted work days lost, costs are analysed taking total annual 
salary, number of working days per year and death benefit proportional factor (all specified in 
the ‘Input Parameters’ worksheet) into account.  
The worksheet ‘Calculated Costs in Detail’ contains various tables related to the categories 
of morbidity, mortality and presenteeism providing a detailed overview of costs for male and 
female employees. The following screenshots shows the table of calculated costs due to 
sickness: 
 
 
 
A summary worksheet ‘Cost Summary’ provides an overview and summary of total costs 
caused by morbidity, mortality and presenteesim: 
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7.2.6 Interventions, Costs & Benefits 
 
The worksheet ‘Interventions, Costs & Benefits’ provides the user with an interface to select 
various intervention packages for the categories ‘Malaria’ and ‘Non-Acute Diseases & Risk 
Factors’ and ‘Acute Diseases’. There are interventions targeted at the whole category of 
diseases as well as on a specific disease. 
When selecting a specific intervention package (e.g. MAL-1 ITN) the annual costs of 
intervention, the annual benefit as well as the cost-benefit ratio and net benefit are 
calculated. In addition, the user can specify values for intervention coverage, annual costs of 
intervention package and estimated reduction of incidence and mortality rate respectively: 
 
 
 
 
 
Based on these user inputs, the predicted impact of the intervention on work days lost is 
calculated. The following screenshot provides an example of the calculation of the cost-
benefit ratio and net benefit when choosing MAL-1 ITN as an intervention against malaria: 
 
 
 
 
When the values of the input parameters are changed, a flag is displayed to indicate that the 
user is about to perform a sensitivity analysis. The baseline values for each intervention 
package are summarized in the ‘Sensitivity Analysis’ section: 
 
 
 
 
 
In addition to predefined interventions a set of three custom interventions can be specified for 
each category and disease. By ungrouping the ‘Edit Interventions’ section (pressing the + 
button on the left side of the worksheet below the specific category or disease respectively) 
the values of the custom interventions like description, duration, coverage, annual costs per 
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employee (taking into account that certain interventions are targeted at sex-specific 
conditions), reduction in incidence and mortality can be adjusted.  
 
 
 
 
The default values of predefined interventions can be changed as well.  
As soon as the default values have been adjusted, these values are now used for calculation 
when selecting a specific intervention in the selection list of a disease or category. 
 
The diseases in the three categories are sorted according to their relative contribution to total 
costs (that means changing the proportion of male/female employees in the ‘Input 
Parameters’ worksheet potentially has an impact on this order). 
 
The worksheet ‘Interventions Summary’ provides a list of all interventions and a predicted 
cost-benefit ratio for all categories and diseases. All interventions which have an impact on 
employee health (through a reduction in incidence/prevalence > 0 or reduction in mortality > 
0) are shown, the others are hidden. 
As soon as the user changes some default values of custom (or predefined) interventions in 
the ‘Interventions, Costs & Benefit’ worksheet, the ‘Interventions Summary’ worksheet is 
instantly updated. 
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7.2.7 Epidemiological data, hospital stays, risk factors, disease duration and 
disability weights 
 
This section of the workbook contains various worksheets that hold epidemiological data, 
data related to hospital stays and proportion of in-patients and outpatients morbidity as well 
as tables summarizing specific data related to disease duration and disability weights.  
The following screenshot shows the epidemiological profile and the top twenty causes of 
outpatient morbidity contained in the ‘Epidemiological Profile’ worksheet: 
 
 
  
 
 
Similarly, the leading causes of death are summarized in the table below: 
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The ‘Risk Factors’ worksheet summarizes the most relevant risk factors and the estimation of 
annual unproductive days. 
 
 
 
The ‘Hospital Stays’ worksheet contains a table summing up the estimated duration of 
hospital stays for the top twenty causes of morbidity: 
 
 
 
The ‘Duration and Disability Weights’ sheet provides an overview of disease durations and 
disability weights for the top twenty causes of morbidity: 
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7.2.8 Various information and WHO CHOICE reference sheet 
 
The last section of the Excel tool provides further information related to hospital treatment 
costs and the WHO-CHOICE initiative. The ‘Hospital Treatment’ sheet summarizes average 
costs per treatment for the top twenty causes of morbidity: 
 
 
 
 
 
The ‘WHO-CHOICE Interventions’ sheet provides further information and links to statistics 
and tools about various intervention types. 
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7.3 Appendix 3: Tables 
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 Information required            
1 
Annual staff strength, 
number of staff 
members each year 
disaggregated by sex 
2008
-
2010 
2007
-
2010 
2007
-
2010 
2009-
2011 
2007
-
2010 none none none 
2008
-
2010 none 
2 
Annual total in new 
Ghana Cedis (GHS) 
for staff medical 
expenses 
2003
-
2010 
2005
-
2010 
2006
-
2010 
part 
2002-
2010 
2006
-
2010 none none none none none 
3 
Annual number of 
medical claims for 
reimbursement made 
2009
-
2010 none 
2006
-
2010 none none none none none none none 
4 
Annual total in GHS of 
salaries expense 
2007
-
2010 
2007
-
2010 
2007
-
2010 
2007-
2010 none none none none none none 
5 
Annual total number 
of sick leave days 
disaggregated by sex 
2006, 
2010 none 
2007
-
2010 none 2010 none none none 
2008
-
2010 none 
6 
Annual number of 
staff turnovers due to 
illness, disability or 
death disaggregated 
by sex none 
2007
-
2010 
2007
-
2010 
2002-
2010, 
2006 
missing none none none none none none 
7 
Annual number of 
compassionate leave 
days none none 
2008
-
2010 none 2010 none none none none none 
            
8 
Monitoring & 
Evaluation reports yes yes yes yes yes yes yes    
9 
Semi- and Annual 
reports yes yes yes yes yes yes yes    
10 KAP GTZ study report        
2005
-
2006 ?  
11 Baseline study 2008  2008    2008 2008    
12 HIV/TB study 2008           
13 
WPP programme 
financial reports for 
programme expenses           
14 
EWP programme  
financial reports for 
programme expenses           
15 
WPP dedicated staff 
costs           
16 
EWP dedicated staff 
costs           
17 
Organisation charts 
current yes yes yes yes yes      
18 
Organisation charts 
previous yes yes yes yes n.a.      
Table 13: Summary table of data sets received. 
